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Abstract
Objectives—Liposomes sterically stabi­
lised with polyethylene glycol (PEG) 
labelled with technetium-99m were tested  
for their ability to image adjuvant 
arthritis in a rat model.
Methods—Adjuvant arthritis was induced  
in the ankle joint o f the left hind foot by 
injection o f M ycobacterium butyricum  in 
Freund’s incomplete adjuvant in the foot 
pad. Seven days later animals received the 
following radiopharmaceuticals labelled  
with 99mTc (a) non-PEG -liposom es, (b) 
PEG-liposomes or (c) non-specific 
human polyclonal IgG. For each of the 
radiopharmaceuticals the in vivo distri­
bution of the radiolabel was monitored  
both scintigraphic ally as well as by count­
ing the dissected tissues at two, eight, and 
24 hours after injection.
Results—The pharmacokinetics o f the 
radiopharmaceuticals differed consider­
ably (half life in the blood; PEG-liposom es 
(18 hours) > 9MTc-IgG  (3 hours) > 
non-PEG liposomes (1 hour)). The 
inflamed focus was visualised with each of  
the agents. The uptake o f each o f the radio­
pharmaceuticals in the inflam ed ankle 
region correlated with their residence 
time in the blood (inflamed joint uptake: 
PEG liposomes (1.15% injected dose (ID)/ 
g)>,J9lnTc-IgG (0.35% ID/g) >non-PEG- 
liposomes (0.05% ID/g)). Quantitative
analysis of the images showed that the 
inflamed ankle to background ratio was 
highest with the PEG-liposom es (7.5 at 24 
hours after injection), while with the other 
two agents this ratio did not exceed 4. 
Conclusion—This study shows that 9^ r e ­
labelled PEG-liposomes may be an excel­
lent agent to visualise arthritis. Increased  
label uptake in the inflamed joint and 
increased target to background ratios can  
be obtained with PEG-liposom es because 
of their long circulating properties. In 
addition to their use as vehicles for scinti­
graphic imaging of arthritis PEG - 
liposomes might also be used for the site 
specific delivery of antirheumatic drugs.
{Ann Rheum Dis 1997556:369-373)
The clinical course of rheum atoid arthritis is 
highly variable, with most patients suffering 
from persistent bu t fluctuating disease activity 
and variable episodes of more active and more 
quiescent inflammation. T he  assessment of the
inflammatory activity in the involved joints is 
im portant, not only for accurate early 
diagnosis, but also to monitor the state of the 
disease and to evaluate the effect of the 
therapeutic regimen. However, because 
considerable interobserver and intraobserver 
variability exists* riiere is a continued interest 
in the development of an objective,, 
quantitative m ethod to assess disease activity in 
the involved joints.
T he use of radiopharmaceuticals in the 
detection of arthritis activity has the 
advantages o f permitting direct imaging by 
means of whole body scintigraphy, while joints 
that are difficult to assess clinically or 
radiographically can be studied as well, A wide 
range of technetium -99m  labelled radiophar­
maceuticals has been proposed to visualise 
rheum atoid arthritis: nanocolloid, methylene 
diphosphonate (M D P), ‘w"Tc-IgG ( ^ r e ­
labelled hum an immunoglobulin G ). The con­
ventional bone scan with ,,,,mT c-M D P is a sen­
sitive test to study bone diseases. It has been 
shown, however, that in patients presenting 
with rheumatoid arthritis bone scans
frequently show increased upcaice m  
alfected joints unrelated to disease activity.1 ' 
In die late 1980s liposomes have been tested to 
image rheumatoid arthritis/ However, the rec­
ognition of these liposomes by cells of the 
mononuclear phagocyte system (MPS) caused 
relative high uptake in liver and spleen., 
concom itant with rapid blood clearance and 
low uptake in the target. In recent years, it has 
been shown that inclusion of polyethylencgly- 
col (PEG), conjugated to phosphatidylech­
añóla mine, in the lipid bilayer, considerably 
decreased the recognition of the liposomes by 
M PS cells/ 1 It is postulated that the flexible and 
hydrophilic PEG-tails cause the formation of a 
water mantle around the liposomes. As a result 
the interaction of liposomes with macromol­
ecules from the surrounding solution is 
reduced and thus the liposomes are protected 
from destruction or opsonisation and recogni­
tion by M PS cells/’ As a result PEG-liposomes 
have an increased residence time in the b lood/ 
In  previous studies we have shown that 
radiolabelled PEG-liposomes accumulate in 
infectious and inflammatory foci w10 because of 
the locally enhanced capillary permeability. 
T he  prolonged residence time in the blood 
enables the PEG-liposomes to extravasa te to a 
relatively high degree at sites of enhanced vas­
cular permeability. Therefore, radiolabelled 
PEG-liposomes may also have potential to 
visualise joints affected by rheumatoid
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arthritis. Moreover, PEG-liposomes can also 
be ‘loaded* with drugs and thus could 
potentially be used for site directed delivery of 
antirheumatic drugs.
In this study we compared the imaging 
potential of y,,mTc-PEG-liposornes with that of 
non-PEG-liposomes and the commercially 
available imaging agent 9UmTc-IgG , in rats with 
adjuvant arthritis.
M e th o d s
ANIMAL MODEL
Adjuvant artiiritis was induced in the left foot 
of randomly bred male Wistar rats (3 m onth 
old, body weight 300 g) as described by Weich- 
m an .11 After ether anaesthesia, 0.1 ml of a sus­
pension o f Mycobacterium butyricum (Difco 
Labs, Detroit, MI) in F reund’s incomplete 
adjuvant (Sigma Chemical Co, St Louis, M O ) 
(10 mg/ml) was injected in the foot pad of the 
left foot. Six days after induction, accumula­
tion of m ononuclear cells in the loose connec­
tive tissues of die foot can be appreciated at 
histological examination. Seven days after the 
inoculation, the respective radiopharm aceuti­
cals were injected via the tail vein.
PREPARATION OF UPOSOMES
Partially hydrogenated e gg-ph o splia tidy 1 choline 
with an iodine value of 40 (PH EPC ) prepared 
as described previously12 was obtained from 
Asahi Chemical Industry Co (Ibarakiken, 
Japan). Cholesterol and glutathione were 
obtained from Sigma (St Louis, M O ). For the 
preparation of PEG-liposomes the polyethyl- 
eneglycol (PEG) 1900 derivative of D SPE (a 
kind gift of Sequus Inc, Menlo Park, CA), 
while for the preparation of the non-PEG - 
liposomes underivitised D SPE (Avanti Polar 
lipids, M ontreal,) was used as an ingredient.
A chloroform/methanol mixture (10/1, v/v) 
containing DSPE, PH EPC , and cholesterol 
was prepared at a molar ratio of 0.15:1.85:1. A 
lipid film was formed by rotary evaporation 
followed by high vacuum to remove residual 
organic solvent. T he lipid film was dispersed at 
room temperature in 50 m M  glutathione in 
H EPES buffer (10 m M  H EPES, 135 m M  
N aC l, pH  7.5) at a phospholipid concentration 
of 120 m M . The liposomes were sequentially 
extruded through polycarbonate filters of 200 , 
100, 80, and 50 nm  pore size (Poretics, Liver­
more, CA). Unentrapped glutathione was 
removed by gel filtration on a 10DG column 
(Bio-Rad, Richmond, CA). T he particle size 
distribution was determined by dynamic light 
scattering (Malvern 4700 system, Malvern, 
UK). T he  liposomes had a mean size of 120 
nm.
LABELLING PROCEDURES
Preformed glutathione containing non-PEG- 
liposomes or PEG-liposomes were labelled with 
99,nTc essentially as described previously.15 ,,,>mTc 
was transported by d,/-hexamediylpropylene 
amine oxime (HMPAO) through the bilayer 
and trapped irreversibly in die internal 
aqueous phase caused by reduction by the 
encapsulated glutadiione. Briefly, 2.0 ml of
liposomes (75 mmol phospholipid/ml) were 
incubated for 15 minutes at room temperature 
with 20 mCi °‘,rnTc-HMPAO. Removal of 
unencapsulated yi>mTc-HMPAO was achieved 
by gel filtration on a 10DG column (Bio-Rad) 
eluted witii 5% glucose.
A Technescan-HIG vial (Mallinckrodt 
Medical, Petten, die Nedierlands) was 
reconstituted widi 20 mCi 99mTc-pertechnetate 
according to die manufacturer’s instructions. 
The resulting ')<)mTc-IgG was used without any 
further purification.
BIODISTRIBUTION STUDIES
Seven days after die inoculation of M  butyricum 
in the foot pad, 45 rats were divided randomly 
into three groups of 15 rats. Each group was 
injected with 100 \.iCi of either ,,,,mTc-labelled 
non-PEG-liposomes, PEG-liposomes or ‘)<JmTc- 
IgG via the tail vein.
At two, eight, and 24 hours after injection, 
five rats of each group were killed with 30 mg 
intraperitoneally injected phenobarbital. Blood 
was obtained by cardiac puncture. After cervi­
cal dislocation, several tissues (inflamed left 
ankle, right ankle, muscle, liver, spleen, kidney, 
intestine, right femur, and bone marrow from 
die right femur) were dissected, weighed, and 
dieir activity was measured in a shielded well 
type gammacounter. To correct for physical 
decay and to permit calculation of the uptake 
of the radiopharmaceuticals in each organ as a 
fraction of the injected dose, aliquots of the 
injected dose were counted simultaneously. 
Inflamed ankle to contralateral ankle uptake 
ratios (IA/CA) were calculated.
IMAGING PROTOCOL
Adjuvant arthritis was induced in another nine 
rats as described above. Seven days later, 
groups of three rats received 300 fiCi o f ‘WmTc- 
labelled non-PEG-liposomes, PEG-liposomes 
or ,,i>mTc-IgG  via the tail vein. Rats were anaes- 
thesised (halothane/nitrousoxide/oxygen) and 
were placed prone on a single head 
gammacamera equipped with a parallel hole 
low energy collimator (Orbiter, Siemens Inc, 
Hoffmann Estates, IL). The three groups of 
rats were imaged synchronously at five 
minutes, one, two, four, six, and 24 hours after 
injection. Symmetric 15% windows were used 
for the 140 keV energy peak. Images (300 000 
counts per image) were obtained and stored in 
a 256 x 256 matrix.
T he  scintigraphic results were analysed by 
drawing regions of interest over die heart 
region, the inflamed foot, over die normal con­
tralateral foot—used as a background region 
— and over die whole anim al Inflamed foot to 
background ratios and percentage residual 
activity in the inflamed foot (inflamed foot to 
whole body ratio) were calculated.
STATISTICAL ANALYSIS
Values are given as mean (SD), Statistical 
analysis was performed using the one way 
analysis of variance test.
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Results
LABELLING AND QUALITY CONTROL OF THE 
RADIOPHARMACEUTICALS
The labelling efficiency of Technescan H IG  10 
minutes after reconstitution with 20 m Ci 
99mT c 0 4 was 97% as determined by instant thin 
layer chromatography (Gelman Labs3 Ann 
Arbor, M I). T h e  non-PEG  and the 
PEG-liposomes were labelled with 99mT c- 
HMPAO with a labelling efficiency of 7 3 % and 
76%3 respectively. Analysis of a sample of each 
of the purified labelled liposome preparations 
on a BioRad 10D G  column indicated that 
more dian 96% of the radioactivity was associ­
ated with the liposomes.
BIODISTRIBUTION STUDIES
Table 1 shows the biodistributions of the 
99mT  c-labelled non-PEG-liposomes^ PEG - 
liposomes,, and 9<JmTc-IgG  in rats with adjuvant 
arthritis induced in the left foot, T he  
non-PEG-liposomal preparation cleared very 
rapidly from the blood: two hours after 
injection blood concentrations had fallen to 
values as low as 0.17 (0.03)% ID/g. These 
non-PEG-liposomes showed relatively high 
uptake in liver and spleen early after injection 
(2.65 (0 .20) and 5.10 (1.09)% ID/g, 
respectively at two hours after injection). In  
contrast, blood clearance of the PEG - 
liposomes was m uch slower (fig 1A). Blood 
concentrations of the 99mTc~IgG preparation 
were intermediate between those of the two 
liposomal preparations at all time points (fig 
1A).
The three radiopharmaceuticals also showed 
considerable differences in uptake in the 
inflamed ankle (table 1). With the 
PEG-liposomes this uptake increased over 
time up to a value of 1.15 (0.18)% ID/g at 24 
hours after injection, while the inflamed ankle 
uptake with the non-PEG-liposomes and the 
y9mTc-IgG remained almost at the same level 
throughout the study period (0.1% ID/g and 
0.5% ID/g, respectively) as shown in figure IB. 
At eight hours and 24 hours after injection the 
IA/CA ratio obtained with the PEG-liposomes 
was significantly higher than die ratio obtained 
with the other two radiopharmaceuticals 
(p<0.05). The IA/CA ratios obtained with the 
PEG-liposomes increased in time up to a value 
of 7.51 (0.91) (fig 2).
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Figure 1 Blood concentration (A) and uptake in the 
inflamed ankle (B) of thev*" Tc-labelled non~PEG-liposonicss 
PEG-liposomes, and ^ Tc-IgG in mts with adjuvant arthritis in 
the left ankle. Five rats per group zoure used, Envr bars rep remit
SD.
Bodi liposomal formulations showed 
relatively high uptake of the radiolabel in the 
spleen, At 24 hours after injection splenic 
uptake was 4.0 (0 .8)% ID/g and 11,1 (1.5)% 
ID /g for non-PE  G and PEG-liposomes, 
respectively. W ith the u,J|1T c-Ig G  preparation 
uptake in die spleen was m uch lower (0.34 
(0.04) % ID/g, 24 hours after injection). With 
this radiopharmaceutical the kidney was the 
organ with the highest activity (7.62 (1.29)% 
ID/g, 24 hours after injection).
IMAGING STUDIES
The inflamed foot was visualised with each of 
the radiopharmaceuticals included in this 
study. Figure 3 shows the image 24 hours after 
injection of the rats that received ‘"^Tc-labelled 
non-PEG-liposomes, PEG-liposomes or
Table 1 Biodistribution o f w"‘Tc-non-PEG-Hposomes,99,11 Tc-PEG-liposomes} and ™"'Tc-IgG in rats with adjuvant arthritis two, eight, and 24 hours after 
injection (%IDlg 5 rats ¡group)
Non-PEG-liposomes PEG-liposomes Tc-?gG
2 hours 8 hours 24 hours 2 hours 8 hours 24 hours 2 hours 8 hours 24 hours
Blood
Inflamed ankle
Unaffected ankle
Muscle
Bone marrow
Femur
Lung
Spleen
Kidney
Liver
Intestine
0.17 (0.03) 
0.10 (0.01) 
0.03 (0.00) 
0.01 (0.00) 
0.29 (0.08) 
0.08 (0.02) 
0,16 (0,05) 
5.01 (1.09) 
3.68 (0.45) 
2.65 (0.20) 
0.12 (0.02)
0.07 (0.01) 
0.11 (0.04) 
0.03 (0.01) 
0.01 (0.00) 
0.25 (0.09) 
0.03 (0.01) 
0.09 (0.02) 
5.04(1.21) 
3.56 (0.71) 
1.81 (0,36) 
0.05 (0.01)
0.03 (0.01) 
0.05 (0.01) 
0.02 (0.00) 
0.00 (0,00) 
0.24 (0.07) 
0.03 (0.01) 
0.07 (0.02) 
4.01 (0.80) 
2.97 (0.43) 
1.28 (0.43) 
0.02 (0.00)
4.27 (0.28) 
0.49 (0.08) 
0.14 (0.02) 
0.05 (0.01) 
0.72 (0.17) 
0.16 (0.03) 
0.95 (0.12) 
6.15 (0,47) 
1.41 (0.24) 
L I 6 (0.23) 
0.62 (0.28)
3.49 (0.33) 
0.77 (0.04) 
0.14 (0.02) 
0.06 (0,02) 
0.83 (0.09) 
0.11 (0.02) 
1.08 (0.23) 
7.84 (0.95) 
1.73 (0.12) 
0.98 (0.21) 
0.71 (0.20)
2.42 (0,33) 
1.15 (0.18) 
0.16 (0.02) 
0.04 (0.01)
I.03 (0.16) 
0.17 (0,02) 
0,70 (0.07)
II .1 (1.46) 
2.60 (0.36) 
0.78 (0.31) 
0.60 (0.04)
2.79 (0.27) 
0.46 (0.05) 
0.16 (0.01) 
0.05 (0.01) 
0.76 (0.08) 
0.20 (0.02) 
0.94 (0.22) 
0.87 (0.11) 
7.84 (0.79) 
1.24 (0.10) 
0.50 (0.05)
1.19 (0.10) 
0.44 (0.05) 
0.11 (0.02) 
0.05 (0.02) 
0.56 (0,12) 
0.09 (0.02) 
0.57 (0.12) 
0.55 (0.09) 
7.80 (0.90) 
0.74 (0.07) 
0.25 (0.04)
0.50 (0.09) 
0.15 (0.03) 
0.08 (0.01 ) 
0.02 (0.01) 
0.32 (0.05) 
0.07 (0.02) 
0.27 (0.05) 
0.34 (0.04) 
7.62 (1.29) 
0.33 (0.08) 
0.13 (0.02)
IA/UA ratio 2,97 (0.35) 4.97 (2.48) 2.96 (0.54) 3.53 (0.62) 5.58 (1.01) 7.51 (0,91) 2.92 (0.49) 3.9 (0.67) 4.27 (0,65)
Data shown as mean (SD).
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°,,mTc-IgG. Quantitative analysis of the images 
clearly showed the main differences in circula­
tory half life of the three agents studied. T he 
initial half life of the activity from the heart 
region of the PEG-liposomes3 the non-PEG -
liposomes, and the <WmTc-IgG was 18 hours, 
one hour, and three hours, respectively (data 
not show n). Furthermore, quantitative analysis 
of die images confirmed die superiority of the 
PEG-liposomes: from four hours onwards the 
uptake in the inflamed foot was significantly 
higher for the PEG-liposomes as compared 
witii die other preparations (p < 0,03) (fig 4). 
Activity in the contralateral foot was low for 
each of the radiopharmaceuticals. Conse­
quently inflamed foot to background ratios 
were highest for the PEG-liposomes as well 
(7.4 (1,1) v  < 3.6 (1,5), 24 hours after 
injection).
Discussion
This study showed that in a rat model 
PEG-liposomes preferentially localise to 
arthritic joints, and thus PEG-liposomes 
potentially could be used (a) to image rheuma­
toid ardiritis or (b) for die site specific delivery 
of antirheumatic drugs. The diagnosis of rheu­
matoid ardiritis in patients with typically 
established disease is relatively easily made, but 
may be more difficult early in the course of the 
disease. An accurate clinical and diagnostic 
evaluation in patients is important because 
early treatment to suppress the inflammatory 
process may prevent progressive damage to 
articular structures. Furthermore, accurate 
assessment of the status of the disease allows a 
more objective way to evaluate the efficacy of 
die therapeutic regimen.
Liposomes, sterically stabilised with PEG, 
have been shown to preferentially localise to 
infectious foci,14 11 In previous studies we have 
shown that sterically stabilised liposomes 
labelled with gamma-emitters can be used to 
image infectious and inflammatory foci in soft 
tissue.H 11 This study in rats with adjuvant 
arthritis showed that ,,gmTc-PEG-liposomes are 
superior to bodi <,gmTc-non-PEG-liposomes as 
well as ,,<>mTc-IgG to image experimental 
arthritis. The PEG-liposomes were superior in 
terms of bodi absolute uptake in the target tis­
sue as well as target to background ratios. Sev­
eral studies in patients with rheumatoid arthri­
tis have shown that g9mTc-IgG is a useful 
imaging agent for the clinical evaluation of 
rheum atoid arthritis,2 ,fi 17 further supporting 
die clinical potential of WmTc-labelled 
PEG-liposomes. In addition, die finding that 
PEG-liposomes displayed the highest absolute 
uptake in the inflammatory foci suggests that 
PEG-liposomes could also be exploited for site 
specific delivery of antirheumatic drugs. It has 
been shown in a rat model that liposomal 
methotrexate is more effective than the free 
drug in adjuvant arthritis.1” We have studied 
the therapeutic potential of using liposomes 
with encapsulated oxygen derived free radical 
scavengers in the model used in this study 
(Corvo et alb unpublished data).
T he  performance of the non-PEG- 
liposomes in this study was comparable with 
the results obtained in previous studies: an 
optimised formulation of non-PEG-liposomes 
evaluated in a rat model of adjuvant ardiritis 
revealed an initial half life of one to two hours, 
with an IA/CA ratio of 4 .10 In clinical studies
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these non-PEG~liposomes labelled with ,}0mT c 
localised to inflamed joints and not to 
non-affected joints.1 120
Previous studies have shown that die 
interaction of PEG-liposomes widi m ononu­
clear cells in the circulation is minimal. There­
fore, most probably the uptake of the 
PEG-liposomes in the inflammatory foci is 
mainly a result of extravasation caused by the 
locally increased vascular permeability. This 
would explain why uptake of the long circulat­
ing liposomes in the inflamed area is much 
higher dian the uptake of die non-PEG - 
liposomes: the persistently high blood concen­
trations of the PEG-liposomes facilitate the 
continued extravasation of the PEG-liposomes 
at the inflammatory focus. T he mechanism of 
die subsequent retention of die liposomes in 
the inflammatory focus remains to be 
elucidated. The increased blood volume in the 
inflamed foot can only partly explain the 
increased uptake of P E G  liposomes in die 
inflamed foot, because the IA/CA ratio 
increased with time. T he IA/CA ratio obtained 
immediately after injection is a result of the 
increased vascularity in the inflamed foot and 
is relauvely low.
Non-specific hum an polyclonal IgG  has 
been shown to localise to foci o f rheumatoid 
arthritis.2 17 21 Initially it was proposed that the 
IgG was trapped specifically because of the 
interaction with Fc receptor positive inflamma­
tory cells.22 However, further studies have 
shown that the role of Fc receptor interaction 
in the accumulation o f IgG  in inflammatory 
foci is minimal.23 Therefore, scintigraphic 
detection of rheumatoid arthritis widi eidier 
IgG or liposomes bodi represent non-specific 
targeting methods, exploiting the increased 
capillary permeability in inflammatory foci. 
Consequently, it is expected that imaging with 
a liposome based radiopharmaceutical cannot 
discriminate rheumatoid arthritis from other 
inflammatory processes in joints. The role of 
radiolabelled liposomes in the diagnostic investi­
gation of patients widi rheumatoid ardiritis has to 
be determined in clinical studies.
In conclusion, this study shows that 
PEG-liposomes may be powerful vehicles for 
scintigraphic imaging of the joints affected by 
rheumatoid arthritis as well as for the targeted 
delivery of antirheumatic drugs.
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